Professor Arri Coomarasamy is the Director of Tommy’s National Centre for Miscarriage Research, with specialist teams in Birmingham, Coventry and London, putting patient priorities at the heart of efforts to tackle the widespread and devastating condition of early pregnancy loss. Professor Coomarasamy received his undergraduate medical training from the University of Birmingham, and completed his subspecialist training in reproductive medicine and surgery at Guy’s Hospital, London. Today he leads a research group at the forefront of early pregnancy care, reproductive medicine and international efforts to reduce maternal mortality. His portfolio includes numerous national and international multicentre randomised controlled trials, including the PROMISE trial (the role of progesterone in women with unexplained recurrent miscarriages), the TABLET trial (levothyroxine therapy for women with thyroid antibodies), the PRISM trial (progesterone therapy for women with early pregnancy bleeding), the RESPONSE trial (G-CSF treatment for recurrent miscarriage), the AIMS trial (the effects of prophylactic antibiotics before miscarriage surgery in low-income countries) and the World Health Organisation (WHO) CHAMPION trial (the role of carbetocin to prevent postpartum haemorrhage). He has published over 130 medical articles in high impact journals such as NEJM and the Lancet.